French immune therapy company raises €12 million

Monday 7 June 2010

The French privately-owned immune therapy company, Cytheris SA, has raised €12 million in a Series D financing to accelerate development of its recombinant human interleukin-7 product, CYT107, for cancer and other indications.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France